Press Releases October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…MaaT PharmaOctober 15, 2024
